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Abstract
Background: Despite the progress in the quality of multiphasic CT and MRI scans, it is still difficult to fully
characterize a solid kidney lesion. Approximately 10% of all solid renal tumours turn out to be oncocytomas. In
actual clinical practice, this is verified only following unnecessary surgery or a renal biopsy/ablation. The objective of
our pilot study examines whether 99mTc-sestamibi SPECT/CT can play a crucial role in the characterization of solid
renal neoplasms and the differentiation of oncocytomas from renal cell carcinomas.
The study included 27 patients identified with 31 solid renal lesions. All patients were discussed in a
multidisciplinary conference, and a decision for surgery or biopsy was taken. Prior to invasive procedures, patients
underwent a SPECT/CT with 99mTc-sestamibi. Visual evaluation was performed, and any focal 99mTc-sestamibi uptake
detected on SPECT in the localisation of tumour was considered as positive.
Results: Eleven out of 12 oncocytomas (91.6%) displayed positive uptake of 99mTc-sestamibi. Three hybrid tumours
(mixed-type oncocytoma and chromophobe renal cancer) were positive on SPECT/CT. One papillary renal cell
carcinoma had a slight uptake of 99mTc-sestamibi. The remaining 11 renal cell carcinomas were sestamibi negative.
Conclusions: Differentiation of benign renal oncocytomas from renal cell carcinomas seems very promising on
99mTc-sestamibi SPECT/CT examination. Additional supplement to visual evaluation, i.e. quantitative tools, should
be sought for an accurate estimate of biological behaviour and hence a secure diagnosis.
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Background
Approximately 1000 renal tumours are newly diagnosed
in Sweden annually [1, 2] with 120 patients out of 250
patients within the Stockholm County being treated at
Karolinska University Hospital for suspected renal cell
carcinoma (RCC). RCCs account for nearly 2% of all
adult cancers worldwide [3]. The most common RCC
subtypes include clear cell, papillary and chromophobe
RCC accounting for 70–80%, 14–17% and 4–8% of
RCCs, respectively [4, 5]. However, the number of
benign renal tumours, often preoperatively misclassi-
fied as potentially malignant, is not negligible since it
varies from 10 up to 20% [6, 7]. In certain studies,
the percentage of benign renal lesions at surgery is
even higher reaching 27% [8]. The spectrum of be-
nign renal lesions that can be mistaken for renal cell
carcinomas encompasses renal oncocytoma, angio-
myolipoma, metanephric adenoma and the infected/
complicated renal cysts [8–10].
Renal oncocytomas are uncommon, but not rare
tumours, since they constitute approximately 10% of
all primary epithelial neoplasms of the adult kidney
[11–13]. Oncocytomas can be mistaken for RCC on
imaging grounds, accounting for 4–10% of nephrectomies
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performed for a suspected RCC [14]. The coincidence of
oncocytoma with RCC is not infrequently encountered. In
addition, renal oncocytomas can be multiple in 6% and bi-
lateral in 5% and can develop metachronic tumours in 4%
of the cases [15].
The detection rate of solid renal lesions might
have increased based on MRI/multiphasic abdominal
CT, but the preoperative differentiation of oncocy-
toma from RCC remains a diagnostic challenge even
for an experienced abdominal radiologist [16–19].
Distinct radiological features such as stellate scars,
contrast uptake patterns, measurements of fat con-
tent, DWI sequences or even subtraction techniques
in MRI scans cannot really resolve the diagnostic
challenge in a definite way [20–22]. Those diagnostic
features are not only unspecific but also directly
dependent on the imaging quality of the examination
scan [17]. In addition, the diagnostic accuracy of the
aforementioned imaging modalities tends to be sig-
nificantly lower in tumours with a diameter of
≤20 mm [23].
Renal oncocytoma is a unique neoplasm given its dis-
tinct intracytoplasmic content, i.e. numerous densely
packed mitochondria [24]. Accordingly, a mitochondrial-
imaging agent 99mTc-sestamibi could potentially trace
oncocytomas arising in the kidneys.
Based on this hypothesis, Gormley et al. concluded in
1996 that 99mTc-sestamibi imaging appeared to play a
role as a non-invasive screening method [25]. Efforts for
scintigraphic preoperative diagnosis of oncocytomas
have been reported even earlier, with another imaging
agent technetium 99m diethylene-triamine-pentaacetate
(Tc-99m DTPA) [26]. However, the rationale behind the
use of this imaging agent with another mechanism of
uptake was not strong enough to support further use of
DTPA for this reason. In this context, recent work from
Rowe and Gorin supported the potential role of 99mTc-
sestamibi SPECT/CT in differentiating benign oncocy-
toma from RCC [27, 28].
Those last promising results encouraged our group to
initiate this prospective pilot study by evaluating
whether molecular imaging utilizing 99mTc-sestamibi




The study was initiated following approval by the
Regional Ethical Review Board and the local Radiation
Safety Committee. A written informed consent was
acquired from all patients who participated in our
study. This explorative, non-randomised prospective
study started in September 2015. Patients with T1
solid renal tumours, eligible for undergoing surgery
or suitable for biopsy, were included. Exclusion cri-
teria were defined as follows: T2+ tumours, tumours
>7 cm in maximum diameter and/or patients with
metastatic disease. Renal impairment was not an ex-
clusion criterion. All patients were discussed in the
kidney tumour conference at the Karolinska Depart-
ment of Radiology at Huddinge, in order to fully
characterize the lesions and examine the operability
indications.
Image acquisition
SPECT/CT imaging was performed upon the injection
of 925 ± 25 MBq 99mTc-sestamibi (produced by the Na-
tional Centre for Nuclear Research, Poland; distributed
by S. Ahlén Medical Nordic AB, Stockholm, Sweden),
1–4 days prior to surgical intervention or biopsy
procedure.
SPECT/CT imaging was initiated 60–90 min after the
injection, on a Siemens Symbia T16 (Siemens Health-
care, Erlangen, Germany) system equipped with low-
energy high-resolution collimators. SPECT imaging was
performed with a 128 × 128 pixel matrix size (zoom fac-
tor 1) acquiring 64 projections in a step-and-shoot
mode. Each projection was acquired during a 40-s time
frame.
Directly following the SPECT acquisition, a CT was
performed, for the purpose of attenuation correction
and anatomical correlation, using 130-kV tube volt-
age, 5-mm slice width and the automatic exposure
control CARE Dose4D activated to provide proper
tube current modulation, with a quality reference
mAs setting of 10.
Reconstruction and evaluation
The SPECT and CT data were reconstructed with HER-
MES Hybrid Recon™ Oncology v.1.1B (HERMES Med-
ical Solutions AB, Stockholm, Sweden). Two consultant
radiologists, including an experienced nuclear medicine
physician and an experienced abdominal radiologist, in-
dependently evaluated scintigraphic studies of the renal
tumours without any prior knowledge of the histopatho-
logical diagnosis.
Any focal 99mTc-sestamibi uptake detected on SPECT
in the localisation of known tumour detected on CT was
regarded as 99mTc-sestamibi positive (sestamibi+),
whereas lesions with 99mTc-sestamibi uptake lower than
normal renal parenchyma were considered to be 99mTc-
sestamibi negative (sestamibi−).
Confirmation of diagnosis
All lesions were biopsied/operated upon with a histo-
pathological diagnosis eligible for analysis.
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Results
Between September 2015 and May 2016, 27 patients
were included in the current study. One patient died
due to other medical issues without any histopatho-
logical verification. Two patients had infected cysts
that reduced in size verified on a CT control prior to
surgery and therefore were not operated. In total, 24
patients were eligible for further analysis with
altogether 31 solid renal tumours evaluated, since 4
patients had multiple bilateral renal lesions. Sixteen
out of 31 lesions were resected whereas the rest were
biopsied. The majority of the lesions had a size
between 21 and 25 mm (Table 1). Despite the restric-
tions of SPECT/CT concerning accurate size measure-
ments, it was easy to localize and measure the size of
the kidney tumour with the help of previous CT stud-
ies that all patients had undergone.
A complete agreement was reached collaboratively be-
tween two readers in evaluating tumours visually and
classifying them into sestamibi+ and sestamibi−. Our co-
hort study contained 12 renal lesions that turned out to
be oncocytomas, 11 of which were sestamibi+ (Fig. 1)
and 1 sestamibi−. The last one was verified upon
resection. In total, 7 out of 12 oncocytomas were
verified histopathologically upon kidney resection.
Three hybrid tumours (oncocytoma and chromophobe
RCC) that were also resected exhibited 99mTc-sesta-
mibi uptake. One angiomyolipoma displayed radioiso-
tope uptake. Among 12 RCCs (7 clear cell RCCs, 3
papillary RCCs and 2 chromophobe RCCs), 11 were
clearly sestamibi− (Fig. 2). Interestingly, 1 papillary
RCC verified upon resection showed a slightly ele-
vated uptake of radiotracer.
One patient with one collision tumour (chromophobe
and papillary RCC) displayed no 99mTc-sestamibi uptake.
Sestamibi− included 1 lymphoma and 1 metanephric
adenoma (Table 2).
Discussion
99mTc-sestamibi is currently a well-established tracer
for routine clinical investigations of myocardial
perfusion and detection of parathyroid adenomas
[29, 30]. Its mechanism of uptake is based on the
tracer’s sequestration within the mitochondria of liv-
ing cells, which can be applied as well on onco-
logical imaging such as scintimammography [31]. As
oncocytomas comprise neoplastic cells filled with
numerous densely packed mitochondria, 99mTc-sesta-
mibi appears to be a suitable tracer to diagnose and
differentiate this benign renal neoplasm from malig-
nant renal tumours.
Based on tumour visual analysis, our data confirms
the hypothesis that oncocytomas show uptake of
99mTc-sestamibi, which is in accordance with the
aforementioned studies [25, 27, 28] with a high true
positive rate. In this pilot study, 11 out of 12 oncocy-
tomas were sestamibi+, resulting in a 91.6% sensitivity
of the method. Similar high true positive rates have
been reported previously from Rowe and Gorin [27,
28]. On histopathological grounds, the single oncocy-
toma that had no radioisotope uptake exhibited a cys-
tic character with one third fibrous tissue. Further
immunohistochemical analysis verified the oncocytic
nature of the lesion according to the histopathological
report.
In our study, a patient turned out to have 3
sestamibi+ solid renal tumours bilaterally. The tu-
mours proved to be hybrid oncocytic-chromophobe
tumours after resection. Similar results about the be-
haviour of those hybrid tumours with oncocytic
components showing sestamibi uptake have been
reported from Gorin et al. [28]. Even if hybrid
Table 1 Size of renal tumours







Fig. 1 The scintigraphic study (a) displays a coronal view of focal radioisotope uptake in the upper pole of right kidney (arrow). Anatomic
correlation of the previous uptake (c) in the CT study, coronal view-venous phase. The coronal SPECT/CT fusion image (b) with sestamibi
uptake in the same solid renal neoplasm (24 mm in maximum diameter) of the right kidney. This was subsequently diagnosed as renal
oncocytoma on histopathological grounds
Tzortzakakis et al. EJNMMI Research  (2017) 7:29 Page 3 of 5
tumours were misdiagnosed as oncocytomas, there is
no evidence of aggressive behaviour based on litera-
ture data. However, no report with a follow-up lon-
ger than 10 years has been published [32].
Another benign entity such as the solitary angio-
myolipoma that our study includes exhibited
sestamibi uptake. This behaviour, of no clinical con-
sequence, is not in accordance with the results
published from the scientific group from John
Hopkins [28] since an angiomyolipoma was reported
as sestamibi negative.
Despite the above promising results, the main clin-
ical question arising is what should be the manage-
ment of false positive lesions, i.e. sestamibi+ papillary
RCC?
Papillary renal cancer with sestamibi uptake
In our pilot study of 31 renal lesions, 1 sestamibi+
tumour turned out to be a papillary RCC. This was con-
firmed upon nephrectomy (International Society of Uro-
logical Pathology, ISUP nucleolar grade 2). Gorin et al.
report false positive results as well [28] due to the pres-
ence of 2 chromophobe renal tumours with sestamibi
uptake.
Accordingly, a simple visual interpretation is inad-
equate for a secure diagnosis despite the fact that the
sestamibi uptake of this papillary RCC was less intense
compared to the uptake of oncocytomas and HOCTs.
The false positive results raise the need of quantitative
tools as an important supplement to visual evaluation.
The quantitative analysis should be applied and evalu-
ated before this method could be recommended for clin-
ical practice.
Conclusions
There are clear benefits in the preoperative
characterization of solid renal lesions using 99mTc-ses-
tamibi SPECT/CT as an aid to clinical evaluation and
a detailed multiphasic CT examination. Solid renal le-
sions without uptake of 99mTc-sestamibi on SPECT/
CT have most probably a malignant character and
should be the subject of surgery. Renal lesions with
positive 99mTc-sestamibi uptake are probably benign
in nature. Were the surgery to be avoided in these
patients, it would require an estimation of the conse-
quences regarding the risk for false positive results.
Even if this risk was low, it was not negligible in our
small cohort of patients. The visual interpretation
could be strengthened by application of quantitative
tools. This should be evaluated before applying
99mTc-sestamibi SPECT/CT in clinical routine.
Fig. 2 Scintigraphic coronal view demonstrates the absence of radioisotope (arrow) in the upper part of left kidney (a). Preoperative CT study,
venous phase in coronal view (c) of the same patient for anatomical correlation of the renal lesion. b Fused coronal SPECT/CT image with a solid
renal neoplasm (28 mm in maximum diameter) of the left kidney without any sestamibi uptake. This was subsequently diagnosed as clear cell
carcinoma on histopathological grounds
Table 2 Characteristics of 31 solid renal lesions in terms of sestamibi uptake
Type of lesions Number of lesions sestamibi positive sestamibi negative
Oncocytoma 12 (39%) 11 (91.6%) 1 (8.4%)
Hybrid (oncocytoma-chromophobe RCC) 3 (10%) 3 (100%) 0
Metanephric adenoma 1 (3%) 0 1 (100%)
Lymphoma 1 (3%) 0 1 (100%)
Angiomyolipoma 1 (3%) 1 (100%) 0
Clear cell RCC 7 (23%) 0 7 (100%)
Papillary RCC 3 (10%) 1 (33.3%) 2 (66.7%)
Chromophobe RCC 2 (6%) 0 2 (100%)
Collision (chromophobe-papillary RCC) 1 (3%) 0 1 (100%)
RCC renal cell carcinoma
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